Develops drugs for post-stroke recovery and substance use disorders.
Dec 2024Revenue CHF 404K/yrExpenses CHF 3.16M/yr
No trendCash runway ≈ 7 months from Dec 2024
Figures by year
When will Addex Therapeutics be profitable?
Its figures don’t show a steady enough trend to project a date. In the 12 months to Dec 2024, revenue was CHF 404K and expenses CHF 3.16M.
| Fiscal year to | Revenue | Expenses | Operating profit |
|---|---|---|---|
| Dec 2024 | CHF 404K | CHF 3.16M | −CHF 2.76M |
| Dec 2023 | CHF 1.61M | CHF 3.86M | −CHF 2.24M |
| Dec 2022 | CHF 1.42M | CHF 12.0M | −CHF 10.5M |
| Dec 2021 | CHF 2.92M | CHF 18.4M | −CHF 15.5M |
| Dec 2020 | CHF 3.61M | CHF 15.9M | −CHF 12.2M |
| Dec 2019 | CHF 2.76M | CHF 17.4M | −CHF 14.6M |
| Dec 2018 | CHF 6.04M | CHF 7.47M | −CHF 1.42M |
| Dec 2017 | CHF 500K | CHF 3.73M | −CHF 3.24M |
When the cash runs out, on the chart. A red line at the date the company’s cash would run out at its latest burn, so you can see whether it gets to break-even first. Part of a subscription.